Search Result

Results for "

colorectal cancers

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (2) Acyltransferase (1) ADC Cytotoxin (2) Akt (10) Aldehyde Dehydrogenase (ALDH) (1) AMPK (3) Amylin Receptor (3) Antibiotic (6) Antibody-Drug Conjugates (ADCs) (1) Antifolate (1) APC (2) Apoptosis (77) Atg8/LC3 (1) Autophagy (26) Bacterial (2) Bcl-2 Family (4) BMI1 (3) c-Fms (3) c-Met/HGFR (2) c-Myc (2) Carbonic Anhydrase (1) Casein Kinase (1) CD3 (1) CDK (9) Checkpoint Kinase (Chk) (1) Cholinesterase (ChE) (1) COX (11) CRAC Channel (1) CRM1 (2) CXCR (1) Cytochrome P450 (4) DAPK (1) Deubiquitinase (3) Dihydroorotate Dehydrogenase (1) DNA/RNA Synthesis (19) Drug-Linker Conjugates for ADC (1) EGFR (6) Endogenous Metabolite (14) Epigenetic Reader Domain (1) ERK (6) FAK (1) FAP (2) Fatty Acid Synthase (FASN) (2) Ferroptosis (1) FLAP (2) FLT3 (1) Fluorescent Dye (1) Fungal (5) FXR (1) Gli (1) GLUT (1) Guanylate Cyclase (1) HDAC (3) Hedgehog (1) HIF/HIF Prolyl-Hydroxylase (2) Histone Methyltransferase (8) HIV (1) HSP (6) HSV (2) Influenza Virus (5) Interleukin Related (1) Isotope-Labeled Compounds (4) Keap1-Nrf2 (1) KLF (2) Lactate Dehydrogenase (1) LAG-3 (1) Ligands for Target Protein for PROTAC (1) MAGL (1) MAP3K (1) MAP4K (1) MAPKAPK2 (MK2) (1) MDM-2/p53 (4) MEK (6) MicroRNA (2) Microtubule/Tubulin (6) Mitochondrial Metabolism (1) MMP (2) Mps1 (1) mTOR (2) Neurotensin Receptor (1) NF-κB (8) NO Synthase (1) Notch (1) Nucleoside Antimetabolite/Analog (3) Orthopoxvirus (2) Oxidative Phosphorylation (3) p38 MAPK (2) Parasite (8) PARP (6) PD-1/PD-L1 (4) PDGFR (3) PDK-1 (1) Phosphatase (1) PI3K (9) Porcupine (1) Potassium Channel (2) Prolyl Endopeptidase (PREP) (1) Prostaglandin Receptor (1) PROTACs (6) Pyruvate Kinase (2) Radionuclide-Drug Conjugates (RDCs) (1) Raf (10) Ras (18) Reactive Oxygen Species (9) ROCK (1) ROS Kinase (3) SARS-CoV (1) Serotonin Transporter (3) Sigma Receptor (1) Sirtuin (1) Somatostatin Receptor (2) Src (2) STAT (4) Survivin (2) TAM Receptor (1) Thymidylate Synthase (2) Tie (1) TNF Receptor (1) Topoisomerase (7) Trk Receptor (3) TRP Channel (2) Tyrosinase (1) ULK (1) VEGFR (7) Wee1 (1) Wnt (11) YAP (1) β-catenin (14)
By Research Areas:	Cancer (281) Cardiovascular Disease (4) Endocrinology (1) Infection (18) Inflammation/Immunology (35) Metabolic Disease (7) Neurological Disease (5)
Oligonucleotides:	Polymers (1)

283

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Peptides

MCE Kits

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Necitumumab	EGFR	Cancer
Necitumumab is a human IgG monoclonal antibody directed against EGFR. Necitumumab can be used for research of NSCLC, colorectal cancer, etc .

Liensinine perchlorate 5+ Cited Publications	Apoptosis	Inflammation/Immunology Cancer
Liensinine Perchlorate is a constituent of?Nelumbo nucifera?Gaertn, with ani-hypertension and anti-cancer activities. Liensinine Perchlorate induces?colorectal cancer (CRC) cell apoptosis .

Pramlintide acetate	Amylin Receptor	Metabolic Disease Cancer
Pramlintide acetate is a polypeptide analogue of human amylin. Pramlintide acetate, an antidiabetic agent, is antineoplastic in colorectal cancer .

SR18662	KLF	Cancer
SR18662 is a potent inhibitor of Krüppel-like factor five (KLF5) with an IC₅₀ of 4.4 nM and an analogue of ML264 (HY-19994) with improved inhibitory potency against colorectal cancer cells. SR18662 can be used for the study of colorectal cancer .

Se-Aspirin Selenium-acetylsalicylic acid	NF-κB	Inflammation/Immunology
Se-Aspirin is a hybrid molecule of selenium and Aspirin (HY-14654). Se-Aspirin reduces the viability of cancer cell lines, particularly colorectal cancer cells .

Pramlintide	Amylin Receptor	Metabolic Disease Cancer
Pramlintide is a polypeptide analogue of human amylin. Pramlintide, an antidiabetic agent, is antineoplastic in colorectal cancer .

Pramlintide TFA	Amylin Receptor	Metabolic Disease Cancer
Pramlintide TFA is a polypeptide analogue of human amylin. Pramlintide TFA, an antidiabetic agent, is antineoplastic in colorectal cancer .

KHKI-01128	AMPK	Cancer
KHKI-01128 is a NUAK2 inhibitor, with an IC₅₀ of 0.024 μM. KHKI-01128 exhibits potent anticancer activity against SW480 colorectal cancer cells .

SMART1	PROTACs PDK-1 Akt	Cancer
SMART1 is a highly specific and CRBN-dependent PROTAC that can effectively degrade Smurf1. SMART1 can block the PDK1-Akt signaling pathway in KRAS mutant colorectal cancer. SMART1 can inhibit tumor growth in KRAS mutant colorectal cancer (CRC) xenograft models.(Blue: CRBN ligand; Black: linker; Pink: Smurf1 ligand (Smurf1-L)) .

TNIK-IN-4	Others	Cancer
TNIK-IN-4 is a potent TNIK inhibitor with IC₅₀ of 0.61 μM. TNIK-IN-4 has inhibitory activity against typical colorectal cancer cell line HCT116 .

RS5517	Others	Cancer
RS5517 is a specific PDZ1-domain antagonist of NHERF1 that prevented its ectopic nuclear entry. RS5517 can be used for the research of colorectal cancer .

PI3Kα-IN-5	PI3K mTOR	Cancer
PI3Kα-IN-5 (compound 6 ab) is a potent PI3Kα/mTOR inhibitor, with an IC₅₀ of 0.7 nM and 3.3 nM, respectively. PI3Kα-IN-5 can be used for the research of colorectal cancer .

B-Raf IN 11	Raf	Cancer
B-Raf IN 11 (ZINC72115182) is a selective B-Raf ^V600E inhibitor (IC₅₀=76 nM), shows selectivity for B-Raf ^V600E over B-Raf ^WT with selectivity of 3.1-fold. B-Raf IN 11 can be used in colorectal cancer research

TRPM4-IN-2 NBA	TRP Channel	Cancer
TRPM4-IN-2 (NBA) is a potent transient receptor potential melastatin 4 (TRPM4) inhibitor with an IC₅₀ value of 0.16 μM. TRPM4-IN-2 can be used for researching prostate cancer and colorectal cancer .

GM-60186	5-HT Receptor	Cancer
GM-60186 is a 5-HT receptor 2B (HTR2B) inhibitor with an IC₅₀ of 257 nM. GM-60186 significantly inhibits colorectal cancer proliferation and migration .

(−)-N-Hydroxyapiosporamide NHAP	NF-κB	Cancer
(−)-N-Hydroxyapiosporamide (NHAP), an alkaloid, is an NF-κB inhibitor with potent antitumor activity in vitro and in vivo. (−)-N-Hydroxyapiosporamide can be used for the research of colorectal cancer (CRC) .

WEE1-IN-8	Wee1	Cancer
WEE1-IN-8 (Compound 55) is a selective WEE1 inhibitor, with an IC₅₀ of 0.98 nM. WEE1-IN-8 (Compound 55) can be used for the research of Pancreatic cancer, Ovarian cancer, Colorectal cancer, Uterine serous carcinoma, etc .

Labetuzumab govitecan IMMU 130; hMN-14-SN-38	Antibody-Drug Conjugates (ADCs)	Cancer
Labetuzumab govitecan (IMMU 130) is an Anti-CEACAM5/SN-38 antibody-drug conjugate (ADC). Labetuzumab govitecan consists of the antibody Labetuzumab, SN-38, and a pH-sensitive Linker. Labetuzumab govitecan can be used for research of cancers, such as colorectal cancer .

CDK8-IN-9	CDK	Cancer
CDK8-IN-9 (compound 22) is a potent type II CDK8 inhibitor with an IC₅₀ value of 48.6 nM. CDK8-IN-9 can inhibit tumor growth and is used in colorectal cancer studies .

DDO-5936 1 Publications Verification	HSP	Cancer
DDO-5936 is a potent and specific Hsp90-Cdc37 PPI inhibitor. DDO-5936 can be used for the research of colorectal cancer .

Cibisatamab	CD3	Cancer
Cibisatamab (CEA-TCB), a T cell bispecific antibody, binds Carcino-Embryonic Antigen (CEA) on cancer cells and CD3 on T cells. Cibisatamab (CEA-TCB) triggers T cell killing of cancer cell lines expressing moderate to high levels of CEA at the cell surface. Cibisatamab (CEA-TCB) can be used for colorectal cancer research .

Enterodiol	Apoptosis Endogenous Metabolite	Cancer
Enterodiol is transformed by human intestinal bacteria from lignans contained in various whole-grain cereals, nuts, legumes, flaxseed, and vegetables. Enterodiol has an apoptotic effect in colorectal cancer (CRC) cells. Anti-cancer activities .

CDK5 inhibitor 20-223 CP668863	CDK	Cancer
CDK5 inhibitor 20-223 is a potent CDK2 and CDK5 inhibitor with IC₅₀s of 6.0 and 8.8 nM, respectively. CDK5 inhibitor 20-223 is an effective anti-colorectal cancer (CRC) agent .

FC-116	Reactive Oxygen Species Apoptosis Microtubule/Tubulin	Cancer
FC-11 is a Tubulin inhibitor that effectively inhibits tumor growth in mice. FC-11 can also induce endoplasmic reticulum (ER) stress to generate excess reactive oxygen species (ROS), leading to mitochondrial damage, thereby promoting apoptosis in colorectal cancer (CRC) cells by targeting microtubules. FC-11 can be used in cancer research .

Sulindac MK-231	NF-κB PD-1/PD-L1	Inflammation/Immunology Cancer
Sulindac (MK-231) is an orally active nonsteroidal anti-inflammatory agent. Sulindac also is an immunomodulatory agent. Sulindac can be used for the research of arthritis of the spine, gouty arthritis and kinds of cancer including colorectal cancer (CRC) and lung cancer .

Sulindac sodium MK-231 sodium	NF-κB PD-1/PD-L1	Infection Inflammation/Immunology Cancer
Sulindac (MK-231) is an orally active nonsteroidal anti-inflammatory agent. Sulindac also is an immunomodulatory agent. Sulindac can be used for the research of arthritis of the spine, gouty arthritis and kinds of cancer including colorectal cancer (CRC) and lung cancer .

MRV03-068	Others	Cancer
MRV03-068 (Compound 2) is a selective colibactin-activated peptidase (ClbP) inhibitor that blocks the genotoxic effect of Colibactin (HY-145930) on eukaryotic cells. MRV03-068 can be used in colorectal cancer research .

MRV03-069	Others	Cancer
MRV03-069 (Compound 3) is a selective colibactin-activated peptidase (ClbP) inhibitor that blocks the genotoxic effect of Colibactin (HY-145930) on eukaryotic cells. MRV03-069 can be used in colorectal cancer research .

KRASG12C IN-13	Others	Cancer
KRASG12C IN-13 (LY3499446) is a potent KRAS G12C inhibitor. KRASG12C IN-13 is promising for research of advanced solid tumors including non-small cell lung cancer and colorectal cancer .

LSN3074753	Raf	Cancer
LSN3074753, an analog of LY3009120 (HY-12558), is a pan-RAF and Raf dimer inhibitor. LSN3074753 demonstrates activity against tumor cells with MAPK pathway activation driven by BRAF monomer or RAF dimers including BRAF- or KRAS-mutant colorectal cancer. LSN3074753 combined with Cetuximab (HY-P9905) shows additive and synergistic effects for colorectal cancer PDX models, particularly those with KRAS or BRAF mutation .

β-catenin-IN-2 1 Publications Verification	β-catenin	Cancer
β-catenin-IN-2 is a potent β-catenin inhibitor, compound H1B1, extracted from patent US20150374662A1. β-catenin-IN-2 can be used for the study of colorectal cancer .

Levoleucovorin Levofolinic acid; Levofolene	Endogenous Metabolite	Cancer
Levoleucovorin (Levofolinic acid) is the pharmacologically active levoisomer of racemic leucovorin. Levoleucovorin can be used as a rescue agent after high-dose Methotrexate (HY-14519) therapy, and in combination with fluorouracil for the research of advanced metastatic colorectal cancer .

Dinaline GOE 1734; PD 104 208; NSC 328786	Others	Cancer
Dinaline (GOE 1734; PD 104 208; NSC 328786) is a potent and orally activity anticancer agent. Dinaline shows cytotoxicity and antitumor activity. Dinaline has the potential for the research of colorectal cancer .

NSC666715	DNA/RNA Synthesis	Cancer
NSC666715 is a strand-displacement activity of DNA polymerase inhibitor. NSC666715 potentiates Temozolomide (HY-17364)-induced DNA damage, cell senescence and apoptosis. NSC666715 can be used for study colorectal cancer .

KY1022	Apoptosis Ras β-catenin Wnt	Cancer
KY1022 is a small molecule destabilizing Ras via targeting the Wnt/β-catenin pathway. KY1022 can inhibit cellular EMT, metastasis and apoptosis. KY1022 can be used for the research of metastatic colorectal cancer .

DBI-2	AMPK Mitochondrial Metabolism	Cancer
DBI-2 is an AMPK activator targeting mitochondrial complex I. DBI-2 disrupts the OXPHOS process, and reduces ATP generation in mitochondria. DBI-2 inhibits the proliferation of colorectal cancer (CRC) cells .

MX106-4C	Survivin	Cancer
MX106-4C is a survivin inhibitor that selectively kills ABCB1-positive colorectal cancer cells. MX106-4C can exert synergistic anticancer effects with Doxorubicin or resensitize drug-resistant ABCB1 cells to Doxorubicin .

PD-L1-IN-2	PD-1/PD-L1	Cancer
PD-L1-IN-2 is a potential tumor immunological agent by inhibiting PD-L1. PD-L1-IN-2 is a Naamidine J derivative and exerts antitumor effects in vivo by reducing PD-L1 expression and enhancing tumor-infiltrating T-cell immunity. PD-L1-IN-2 is used for colorectal cancer research .

CRM1-IN-1	CRM1	Cancer
CRM1-IN-1 (Compound KL1) is a noncovalent CRM1 inhibitor. CRM1-IN-1 induces nuclear CRM1 degradation (IC₅₀: 0.27 μM). CRM1-IN-1 inhibits CRM1-mediated nuclear export and cell proliferation, and triggers apoptosis in colorectal cancer cells .

Sulindac (Standard)	NF-κB PD-1/PD-L1	Inflammation/Immunology Cancer
Sulindac (Standard) is the analytical standard of Sulindac. This product is intended for research and analytical applications. Sulindac (MK-231) is an orally active nonsteroidal anti-inflammatory agent. Sulindac also is an immunomodulatory agent. Sulindac can be used for the research of arthritis of the spine, gouty arthritis and kinds of cancer including colorectal cancer (CRC) and lung cancer .

YW2065	β-catenin	Cancer
YW2065 is an Axin-1 stabilizer. Axin-1 is a scaffolding protein that regulates proteasome degradation of β-catenin. YW2065 exhibits anti-colorectal cancer effects via dual activities of wnt/β-catenin signaling inhibition and AMPK activation .

Anticancer agent 193	Ferroptosis Reactive Oxygen Species Autophagy	Cancer
Anticancer agent 193 (compound D3-3) is an inducer of ferritinophagy, eventually triggering ferroptosis. Anticancer agent 193 induces the production of lipid ROS, and significantly promoted colorectal cancer cells to release the ferrous ion in an autophagy-dependent manner .

ABP 215	VEGFR	Cancer
ABP 215 (Bevacizumab-awwb), a Bevacizumab (Bevacizumab (HY-P9906)) biosimilar, is a humanized IgG1 monoclonal antibody targeting VEGFA (VEGFR). ABP 215 has anticancer effects, and can be used metastatic colorectal cancer (mCRC) research .

TNIK-IN-5	Wnt	Cancer
TNIK-IN-5 is an efficient TNIK inhibitor with IC₅₀ of 0.05 μM. TNIK-IN-5 efficiently inhibits Wnt signaling in intact cells. TNIK-IN-5 shows excellent in vitro anti-colorectal cancer activity .

AP-4-139B	HSP	Cancer
AP-4-139B is a heat shock protein 70 inhibitor (IC₅₀=180 nM). HSP70 is a protein that is overexpressed in many types of cancer and is closely related to the survival and proliferation of tumor cells. AP-4-139B exhibits significant cytotoxicity to tumor cells, particularly in colorectal cancer cells. AP-4-139B can be used for cancer research .

KRAS G12C inhibitor 61	ERK Ras	Cancer
KRAS G12C inhibitor 61 (Example 3) inhibits phospho-ERK 1/2 in MIA PaCa-2 cells with an IC₅₀ value of 9 nM. KRAS G12C inhibitor 61 can be used for research of pancreatic, colorectal, and lung cancers .

Cat. No.	Product Name

HY-L103

Anti-Colorectal Cancer Compound Library

1,725 compounds

Colorectal cancer (CRC), also known as bowel cancer, colon cancer, or rectal cancer, arises as adenocarcinoma from glandular epithelial cells of the large intestine comprised of the colon and rectum. The majority of cases of CRC are sporadic and result from risk factors, such as a sedentary lifestyle, obesity, processed diets, alcohol consumption and smoking. CRC is also a common preventable cancer.

Studies showed several cellular signaling pathways dysregulated in CRC, leading to the onset of malignant phenotypes. Therefore, it is necessary to analyze the signaling pathways involved in the occurrence and development of colorectal cancer to study the progression and drug treatment of colorectal cancer. Among them, Wnt/β-catenin, p53, TGF-β/SMAD, NF-κB, Notch, VEGF and other target genes and signaling pathways are the focus of research. MCE offers a unique collection of 1,725 compounds with identified and potential anti-colorectal cancer activity. MCE anti-colorectal cancer compound library is a useful tool for anti-colorectal cancer drugs screening and other related research.

Cat. No.	Product Name	Type

HY-D1456

TEPC466

Fluorescent Dyes/Probes

TEPC466 is a novel TEPP-46-based aggregation-induced emission (AIE) probe. TEPC466 shows a high degree of selectivity and sensitivity for the detection of PKM2 protein via the AIE effect. EPC466 can be used for the detection of PKM2. TEPC466 is successfully applied in imaging the PKM2 protein in colorectal cancer cells with low toxicity. TEPC466 is a useful tool for cancer diagnosis and research .

HY-114491

Rineterkib

Fluorescent Dyes/Probes

Rineterkib (compound B) is an orally available ERK1 and ERK2 inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly related to the treatment of KRAS-mutant NSCLC, BRAF-mutant NSCLC, KRAS-mutant pancreatic cancer, KRAS-mutant colorectal cancer (CRC) and KRAS-mutant ovarian cancer. Rineterkib hydrochloride can also inhibit RAF .

HY-D2095

Medical fluorophore 33	Fluorescent Dyes/Probes
Medical fluorophore 33 is a novel quinoline-isoquinoline salt. Medical fluorophore 33 exhibits a strong fluorescent signal, good microsomal stability and high biocompatibility in vivo. Medical fluorophore 33 has antitumor activity in colorectal cancer mice .

Cat. No.	Product Name	Target	Research Area

HY-P0058B

Pramlintide acetate	Amylin Receptor	Metabolic Disease Cancer
Pramlintide acetate is a polypeptide analogue of human amylin. Pramlintide acetate, an antidiabetic agent, is antineoplastic in colorectal cancer .

HY-P0234

Neurotensin 2 Publications Verification	Neurotensin Receptor	Endocrinology Cancer
Neurotensin, a gut tridecapeptide, acts as a potent cellular mitogen for various colorectal and pancreatic cancers which possess high-affinity neurotensin receptors (NTR).

HY-P1201

Cyclosomatostatin	Somatostatin Receptor	Cancer
Cyclosomatostatin is a potent somatostatin (SST) receptor antagonist. Cyclosomatostatin can inhibit somatostatin receptor type 1 (SSTR1) signaling and decreases cell proliferation, ALDH+ cell population size and sphere-formation in colorectal cancer (CRC) cells .

HY-P5819A

xStAx-VHLL TFA	PROTACs β-catenin	Cancer
xStAx-VHLL TFA, a PROTAC, sustains β-catenin degradation and manifested strong inhibition of Wnt signaling. xStAx-VHLL TFA promotes β-catenin ubiquitination .

HY-P0058

Pramlintide	Amylin Receptor	Metabolic Disease Cancer
Pramlintide is a polypeptide analogue of human amylin. Pramlintide, an antidiabetic agent, is antineoplastic in colorectal cancer .

HY-P0058A

Pramlintide TFA	Amylin Receptor	Metabolic Disease Cancer
Pramlintide TFA is a polypeptide analogue of human amylin. Pramlintide TFA, an antidiabetic agent, is antineoplastic in colorectal cancer .

HY-P2569

Malformin A1	Apoptosis	Cancer
Malformin A1, a cyclic pentapeptide isolated from Aspergillus niger, possess a range of bioactive properties including antibacterial activity. Malformin A1 shows potent cytotoxic activities on human colorectal cancer cells. Malformin A1 induces apoptosis by activating PARP, caspase 3, -7, and -9 .

HY-P2269

MAIT-203	Peptides	Cancer
MAIT-203, a cyclopentyalanin-derived peptidomimetic, potently inhibits the interaction of adenomatous polyposis coli (APC) and Asef (RhoGEF4), but not APC-Sam68 or APC-striatin interactions. MAIT-203 binds APC-ARM with a K_i of 0.015 μM and a K_d of 0.036 μM. MAIT-203 significantly represses the migration and invasion of colorectal cancer cells.

HY-P3099

Uroguanylin (human)	Guanylate Cyclase	Cancer
Uroguanylin (human) is a natural ligand for the Guanylyl Cyclase (GCC) receptor expressed in metastatic colorectal cancer tumors. Uroguanylin (human) has anti-tumor actions in an animal model for human colon cancer .

HY-P1201A

Cyclosomatostatin TFA	Somatostatin Receptor	Cancer
Cyclosomatostatin TFA is a potent somatostatin (SST) receptor antagonist. Cyclosomatostatin TFA can inhibit somatostatin receptor type 1 (SSTR1) signaling and decreases cell proliferation, ALDH+ cell population size and sphere-formation in colorectal cancer (CRC) cells .

HY-P6083

RTSPSSR	Peptides	Others Cancer
RTSPSSR is synthesized peptide, which binds specifically to claudin-1 and visulizes the CRC tumor in mice, through near-infrared fluorescence imaging .

HY-D2363

DOTA.SA.FAPi TFA	Radionuclide-Drug Conjugates (RDCs) FAP Prolyl Endopeptidase (PREP)	Cancer
DOTA.SA.FAPi TFA is a bifunctional DATA5m and DOTA chelator, which is composed of the squaric acid and UAMC1110. DOTA.SA.FAPi TFA inhibits fibroblast activation protein (FAP) with an IC₅₀ of 0.9 nM. DOTA.SA.FAPi TFA targets protease PREP with an IC₅₀ of 5.4 μM. DOTA.SA.FAPi TFA can be used a PET tracer, when labeled with ⁶⁸Ga, and used for research about cancer .

HY-P2272

NLS-StAx-h	Wnt β-catenin	Cancer
NLS-StAx-h is a selective, cell permeable, stapled peptide Wnt signaling inhibitor with an IC₅₀ of 1.4 μM. NLS-StAx-h efficiently inhibits β-catenin-transcription factor interactions. NLS-StAx-h shows anti-proliferation of cancer cells .

HY-P5819

xStAx-VHLL	Wnt APC PROTACs β-catenin	Cancer
xStAx-VHLL is a PROTAC β-catenin degrader that manifests strong inhibition of Wnt signaling and sustains degradation of β-catenin in cancer cells and the intestinal organoids derived from wild-type and APC ^–/– mice. xStAx-VHLL can be used as a promising anticancer agent .

Cat. No.	Product Name

HY-K6104

*Human Colorectal* Cancer Organoid Kit**
MCE Human Colorectal Cancer Organoid Kit contains Colorectal Cancer Organoid Basal Medium A, Colorectal Cancer Organoid Supplement B (50×), Colorectal Cancer Organoid Supplement C (250×). This product can be used to efficiently construct human colorectal cancer organoid.

Cat. No.	Product Name	Target	Research Area

HY-P9964

Necitumumab	EGFR	Cancer
Necitumumab is a human IgG monoclonal antibody directed against EGFR. Necitumumab can be used for research of NSCLC, colorectal cancer, etc .

HY-P99011

Cibisatamab	CD3	Cancer
Cibisatamab (CEA-TCB), a T cell bispecific antibody, binds Carcino-Embryonic Antigen (CEA) on cancer cells and CD3 on T cells. Cibisatamab (CEA-TCB) triggers T cell killing of cancer cell lines expressing moderate to high levels of CEA at the cell surface. Cibisatamab (CEA-TCB) can be used for colorectal cancer research .

HY-P99362

Ensituximab Anti-MUC5AC Reference Antibody (ensituximab); NEO-102	Inhibitory Antibodies	Cancer
Ensituximab (NEO-102; NPC-1C) is a chimeric monoclonal IgG1 antibody targeting a variant of MUC5AC. Ensituximab shows specificity to colorectal and pancreatic cancer .

HY-P99275

Patritumab 1 Publications Verification Human Anti-ERBB3 Recombinant Antibody	EGFR Akt ERK PARP Survivin	Cancer
Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody to ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors .

HY-P99406

Petosemtamab MCLA 158	EGFR	Cancer
Petosemtamab (MCLA 158) is an anti- EGFR (K_d: 0.22 nM) and anti-LGR5 (K_d: 0.86 nM) monoclonal antibody (mAb). Petosemtamab leads to EGFR signaling blockade and receptor degradation in LGR5+ cancer cells. Petosemtamab can be used in the research of solid tumors, such as head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer (CRC) .

HY-P99269

Sibrotuzumab BIBH 1; Anti-Human FAP Recombinant Antibody	FAP	Cancer
Sibrotuzumab (BIBH 1) is a humanized IgG1 monoclonal antibody targets fibroblast activation protein (FAP). Sibrotuzumab can be used for the research of colorectal cancer and non-small cell lung cancer (NSCLC) .

HY-P99613

Favezelimab MK-4280	LAG-3	Cancer
Favezelimab (MK-4280) is a humanized anti-LAG-3 monoclonal antibody that blocks the interaction between LAG-3 and its ligand MHC class II. Favezelimab has the potential for colorectal cancer (CRC) research combined with the PD-L1 inhibitor Pembrolizumab (HY-P9902) .

HY-P99215

Parsatuzumab Anti-EGFL7; RG 7414	VEGFR	Cancer
Parsatuzumab (Anti-EGFL7; RG 7414) is a humanized monoclonal antibody, acts as an immunomodulator and binds to EGFL7. Parsatuzumab selectively blocks the interaction between EGFL7 and endothelial cells, potentially inhibiting vascular regrowth and reducing vascular endothelial growth factor (VEGF) inhibition .

HY-P99476

ABP 215	VEGFR	Cancer
ABP 215 (Bevacizumab-awwb), a Bevacizumab (Bevacizumab (HY-P9906)) biosimilar, is a humanized IgG1 monoclonal antibody targeting VEGFA (VEGFR). ABP 215 has anticancer effects, and can be used metastatic colorectal cancer (mCRC) research .

Cat. No.	Product Name	Chemical Structure

HY-10582S

Flurbiprofen-d3

Flurbiprofen-d₃ is the deuterium labeled Flurbiprofen. Flurbiprofen (dl-Flurbiprofen) is a potent, orally active nonsteroidal anti-inflammatory agent (NSAIA/NSAID), with antipyretic and analgesic activities. Flurbiprofen is commonly used for the research of inflammatory diseases, including osteoarthritis and rheumatoid arthritis. Flurbiprofen is a non-selective cyclooxygenase (COX) inhibitor that can be used for the research of colorectal cancer[1][2][3].

HY-10582S1

Flurbiprofen-d5

Flurbiprofen-d₅ is the deuterium labeled Flurbiprofen. Flurbiprofen (dl-Flurbiprofen) is a potent, orally active nonsteroidal anti-inflammatory agent (NSAIA/NSAID), with antipyretic and analgesic activities. Flurbiprofen is commonly used for the research of inflammatory diseases, including osteoarthritis and rheumatoid arthritis. Flurbiprofen is a non-selective cyclooxygenase (COX) inhibitor that can be used for the research of colorectal cancer[1][2][3].

HY-16560S

Camptothecin-d5

Camptothecin-d₅ is the deuterium labeled Camptothecin. Camptothecin (CPT), a kind of alkaloid, is a DNA topoisomerase I (Topo I) inhibitor with an IC50 of 679 nM[1]. Camptothecin (CPT) exhibits powerful antineoplastic activity against colorectal, breast, lung and ovarian cancers, modulates hypoxia-inducible factor-1α (HIF-1α) activity by changing microRNAs (miRNA) expression patterns in human cancer cells[2][3].

HY-10582S2

Flurbiprofen-13C,d3

Flurbiprofen- ¹³C,d₃ is the ¹³C- and deuterium labeled Flurbiprofen. Flurbiprofen (dl-Flurbiprofen) is a potent, orally active nonsteroidal anti-inflammatory agent (NSAIA/NSAID), with antipyretic and analgesic activities. Flurbiprofen is commonly used for the research of inflammatory diseases, including osteoarthritis and rheumatoid arthritis. Flurbiprofen is a non-selective cyclooxygenase (COX) inhibitor that can be used for the research of colorectal cancer[1][2][3].

HY-163587

PRMT5-IN-39-d3
PRMT5-IN-39-d3 is the deuterated form of PRMT5-IN-39. PRMT5-IN-39-d3 is an orally active PRMT5 inhibitor and can be used for study of cancer .

HY-163591

PRMT5-IN-36-d3
PRMT5-IN-36-d3 is the deuterated derivative of PRMT5-IN-36. PRMT5-IN-36-d3 (compound 4) is an orally active PRMT5 inhibitor for cancer research .

HY-10582S3

Flurbiprofen-d4

Flurbiprofen-d₄ is deuterated labeled Flurbiprofen (HY-10582). Flurbiprofen (dl-Flurbiprofen) is a potent, orally active nonsteroidal anti-inflammatory agent (NSAIA/NSAID), with antipyretic and analgesic activities. Flurbiprofen is commonly used for the research of inflammatory diseases, including osteoarthritis and rheumatoid arthritis. Flurbiprofen is a non-selective cyclooxygenase (COX) inhibitor that can be used for the research of colorectal cancer .

HY-13653S1

(-)-Epigallocatechin Gallate-d4

(-)-Epigallocatechin Gallate-d4 (EGCG-d4) is the deuterium labeled (-)-Epigallocatechin Gallate (HY-13653). (-)-Epigallocatechin Gallate (EGCG) is a major polyphenol in green tea, which can inhibit cell proliferation and induce cell apoptosis. (-)-Epigallocatechin Gallate inhibits glutamate dehydrogenase 1/2 (GDH1/2, GLUD1/2) activity. (-)-Epigallocatechin Gallate has a potent anticancer, antioxidant and anti-inflammatory properties against various types of cancers such as colorectal cancer, myeloid leukemia, thyroid carcinoma .

HY-163816

Antiproliferative agent-53-d3

Antiproliferative agent-53-d3 (Compound C1) is an inhibitor for theta-mediated end joining (TMEJ) in HEK293 cell with an IC₅₀ of 0.14 µM. Antiproliferative agent-53-d3 is the inhibitor for CYP2C19 and CYP2C9 with IC₅₀ of 0.77 and 3.1 µM. Antiproliferative agent-53-d3 inhibits the proliferation of DNA repair-compromised cells, with IC₅₀ of 8.1 µM for BRCA2 ^-/- DLD-1. Antiproliferative agent-53-d3 exhibits good pharmacokinetic characteristics in CD-1 mice .

HY-B1490AS3

Imipramine-d4-1

Imipramine-d4-1 is the deuterium labeled Imipramine (HY-W010179). Imipramine is an orally active tertiary amine tricyclic antidepressant. Imipramine is a Fascin1 inhibitor with antitumor activities. Imipramine also inhibits serotonin transporter with an IC₅₀ value of 32 nM. Imipramine stimulates U-87MG glioma cells autophagy and induces HL-60 cell apoptosis. Imipramine shows neuroprotective and immunomodulatory effects .

Cat. No.	Product Name		Classification

HY-145396

PLGA-PEG-NH2		Polymers
PLGA-PEG-NH2 is a material to synthesis nanomicelles. PLGA-PEG-NH2 nanomicelle is an efficient delivery system of Irinotecan for targeted colorectal cancer and hepatocellular carcinoma .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks